Pen Needles Market Size, Share, Growth, Analysis, Report, 2034
| Drivers | Market Impact |
|---|---|
| Prevalence of Diabetes | The expanding patient population with type 1 and type 2 diabetes supports demand for pen needles used for regular insulin administration and blood glucose management. |
| Adoption of Insulin Pen Devices | The preference for insulin pens over conventional vial-and-syringe systems encourages pen needle consumption due to their portability, ease of handling, and suitability for routine insulin delivery. |
| Demand for Home-Based Diabetes Management | The shift toward self-administered diabetes care supports the use of pen needles among patients who require frequent insulin injections outside healthcare facilities. |
| Diabetes Care Infrastructure | Wider availability of diabetes clinics, pharmacies, specialty healthcare services, and patient education programs improves access to insulin delivery devices and supports pen needle adoption. |
| Awareness of Diabetes Management and Treatment Adherence | Greater awareness of regular insulin administration and effective diabetes management encourages patients to use convenient injection devices, including insulin pens and compatible pen needles. |
Risk of Needlestick Injuries and Improper Usage Creates Safety Concerns
Pen needles require proper handling, usage, and disposal to ensure safe insulin administration. Improper injection techniques, repeated needle usage, and accidental needle exposure can increase the risk of needlestick injuries, contamination, and injection-related complications. These safety concerns can reduce patient confidence, create challenges in maintaining consistent usage practices, and increase the need for proper patient education and safe disposal systems.
02High Cost of Advanced Pen Needles Limits Patient Affordability
Advanced pen needles incorporate ultra-thin designs, specialized coatings, and safety features that require additional manufacturing precision and quality-control measures. These technologies can increase production expenses and result in higher retail prices compared with conventional pen needles. The additional cost can create affordability challenges for price-sensitive patients, particularly those requiring regular insulin injections, potentially limiting the adoption of advanced pen needle products.
03Impact Analysis of Key Restraints in Pen Needles Market
01Development of Pen Needles for Pediatric and Neonatal Patients
Medical device manufacturers, pediatric diabetes care providers, and healthcare institutions can develop specialized pen needles with suitable lengths and designs for younger patients who require insulin administration. Revenue opportunities include specialized product sales, hospital supply contracts, and partnerships with pediatric diabetes care programs. Companies such as BD and Novo Nordisk have relevant diabetes injection device expertise.
02Pen Needle Distribution Through Online Pharmacies
Pen needle manufacturers, pharmaceutical distributors, and digital pharmacy platforms can expand online availability to improve product accessibility for patients who require regular supplies. Commercial opportunities include direct-to-consumer sales, subscription-based replenishment services, bulk purchasing agreements, and partnerships with online pharmacies.
By Product TypeStandard Pen Needles are expected to register a CAGR of 7.96% during the forecast period, supported by their established use in insulin administration and compatibility with widely used pen devices.
Safety Pen Needles are anticipated to record a CAGR of 9.31% during the forecast period, driven by demand for safer injection practices, reduced needlestick injuries, and improved patient and healthcare worker protection.
Request Customization to receive a tailored report.
By Needle LengthThe 4mm segment accounted for a share of 31.5% in 2025, supported by its suitability for subcutaneous injections, ease of use, and reduced risk of intramuscular injection.
A CAGR of 8.78% during the forecast period is anticipated for 5mm needles, driven by their suitability for different patient requirements and compatibility with pen-based injection devices.
By Therapy TypeThe Insulin segment accounted for a share of 68.7% in 2025, owing to the widespread use of insulin therapy for blood glucose management among people with diabetes.
GLP-1 therapy is expected to record a CAGR of 10.36% during the forecast period, driven by increasing adoption of GLP-1 medications for diabetes management and weight control.
By UsabilityReusable Pens are projected to register a CAGR of 7.88% during the forecast period, supported by their repeated use, compatibility with replaceable cartridges, and suitability for long-term therapy.
Disposable Pens are anticipated to record a CAGR of 9.16% during the forecast period, driven by convenience, reduced handling requirements, and improved ease of use for patients.
By Mode Of DistributionRetail distribution is expected to register a CAGR of 8.58% during the forecast period, supported by the accessibility of medical supplies through pharmacies and other retail outlets.
Non-retail distribution is anticipated to record a CAGR of 8.03% during the forecast period, driven by institutional procurement and supply requirements across hospitals, clinics, and healthcare facilities.
Speak to an Analyst to discuss market opportunities.
Pen Needles Market Regional OutlookNorth America Pen Needles MarketThe North America pen needles market accounted for a dominant share of 38.6% in 2025.
U.S. Pen Needles MarketThe U.S. has an established diabetes management ecosystem supported by healthcare providers, pharmacies, and medical device manufacturers. Patients with diabetes use insulin pens and compatible pen needles for convenient and controlled insulin administration. The availability of different needle lengths, gauges, and safety-engineered designs supports product adoption across hospitals and home healthcare settings.
Canada Pen Needles MarketCanada's established diabetes care services and access to insulin delivery devices support demand for pen needles. Healthcare providers and patients use pen-based injection systems for routine insulin administration and diabetes management. Pharmacy distribution networks, public healthcare services, and increasing emphasis on convenient self-administration support product availability.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Pen Needles MarketEurope pen needles market is the fastest-growing region in the Pen Needles Market with a CAGR of 9.28% during the forecast period, making it the fastest-growing regional market.
U.K. Pen Needles MarketThe U.K.'s established diabetes care infrastructure and access to insulin therapies support demand for pen needles. Healthcare providers prescribe insulin pen systems for patients requiring routine insulin administration, while home-based diabetes management supports the use of disposable pen needles. Product availability through pharmacies and healthcare services further contributes to adoption.
Germany Pen Needles MarketGermany's established healthcare system, pharmaceutical industry, and medical device sector support demand for pen needles. Patients and healthcare providers use insulin pen systems for convenient and controlled medication delivery. The availability of advanced injection devices, safety-focused needle designs, and established medical supply distribution channels supports market adoption.
Asia Pacific Pen Needles MarketAsia Pacific pen needles market is projected to register a CAGR of 8.74% during the forecast period.
China Pen Needles MarketChina's expanding diabetes care infrastructure and pharmaceutical distribution network support demand for pen needles. The use of insulin pen devices across hospitals, clinics, and home healthcare settings creates demand for compatible disposable needles. Wider access to diabetes treatment and the availability of different injection device options further support adoption.
India Pen Needles MarketIndia's expanding diabetes treatment infrastructure and increasing access to insulin delivery devices support demand for pen needles. Patients use insulin pens for routine medication administration, particularly in outpatient and home healthcare settings. Pharmaceutical distribution networks, medical device availability, and increasing awareness of diabetes management contribute to product adoption.
Japan Pen Needles MarketJapan's established healthcare infrastructure and advanced medical device industry support demand for pen needles. Insulin pen systems are used across hospitals, outpatient facilities, and home healthcare environments for diabetes management. Demand for convenient injection methods, precision-engineered needles, and patient-friendly medical devices further supports adoption.
Competitive LandscapeThe pen needles market is moderately consolidated, with competition involving medical device manufacturers, diabetes care product developers, injection technology providers, and specialized needle manufacturers. The leading players in the market include BD, Novo Nordisk, and Ypsomed, accounting for 30–35% of the global pen needles market share.
Established players compete primarily on needle sharpness, injection comfort, product safety, manufacturing precision, compatibility with insulin pens, regulatory compliance, and global distribution networks. Emerging and specialized players in the pen needles market ecosystem compete through ultra-thin needle designs, advanced lubrication technologies, reduced injection pain, improved patient-friendly features, innovative safety mechanisms, and cost-effective solutions for diabetes management.
List of Key and Emerging Players in Pen Needles Market Links Medical Product Becton, Dickinson and Company (U.S.) Novo Nordisk A/S (Denmark) B. Braun Melsungen AG (Germany) Ypsomed Holding AG (Switzerland) Owen Mumford Ltd. (United Kingdom AdvaCare Pharma (U.S.) Montmed Inc. (U.S.) Allison Medical (U.S.) Terumo Corporation (Japan) UltiMed, Inc. (U.S. Van Heek Medical (Netherlands) HTL-STREFA S.A. (Poland) Hindustan Syringes & Medical Devices Ltd. (India) Igaku Needles (Japan) Links Medical Products Inc. (Canada) Medexel Co., Ltd. (South Korea) Narang Medical Limited (India) Medivena (Germany) Nipro Europe Group Companies (Netherlands)Key Industry Developments June 2026 – Medtronic Launches InPenTM App Integration with SimpleraTM Sync CGMMedtronic introduced integration between its InPenTM smart insulin pen system and the SimpleraTM Sync continuous glucose monitoring (CGM) sensor. The enhancement enables real-time glucose insights and optimized insulin dose recommendations, improving the overall smart insulin injection ecosystem that utilizes disposable pen needles. May 2026 – Embecta Expands Pen Needle Portfolio with Enhanced Safety Features
Embecta Corp. expanded its diabetes injection portfolio by introducing advanced safety-engineered pen needles designed to minimize accidental needlestick injuries while improving patient comfort. The new products support insulin and GLP-1 therapy across hospital and home-care settings. February 2026 – Owen Mumford Enhances Unifine® Pentips® Range
Owen Mumford expanded its Unifine® Pentips® pen needle portfolio with improved ultra-thin wall technology and optimized needle geometry to reduce injection force and enhance patient comfort for diabetes management. The products are compatible with major insulin and GLP-1 injection pens ScopeSegmentation By Product Type 2
- Standard Pen Needles Safety Pen Needles
- 4mm 5mm 6mm 8mm 10mm 12mm
- Insulin GLP-1 Growth Hormone Therapy Obesity Others
- Reusable Pens Disposable Pens
- Retail Non-retail
- U.S. Canada
- U.K. Germany France Spain Italy Russia Nordic Benelux
- China Korea Japan India Australia Taiwan South East Asia
- UAE Turkey Saudi Arabia South Africa Egypt Nigeria
- Brazil Mexico Argentina Chile Colombia
Customize This Report to Match Your Strategic Objectives
Frequently Asked Questions (FAQs) The pen needles market size is valued at USD 4.17 Billion in 2026 and is projected to reach USD 10.10 Billion by 2034, at a CAGR of 11.7% during the forecast period 2026-2034. North America dominated the market with a share of 38.6% in 2025. The leading players in this market are BD, Novo Nordisk, B. Braun Melsungen AG, Ypsomed Holding AG, Owen Mumford Ltd. The pen needles market is projected to grow at a CAGR of 11.7% during the forecast period of 2026 2034.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment